Dante Genomics
Hereditary Cancer Panel Plus
Hereditary Cancer Panel Plus
The Dante Hereditary Cancer Panel Plus focuses on identifying germline mutations in 146 genes associated with an elevated risk of hereditary cancer development.
This comprehensive solution ensures thorough analysis of the most clinically relevant genes with high coverage, all delivered quickly and affordably. Utilizing next-generation sequencing, it provides valuable insights into the risk of developing various hereditary cancers, such as breast, ovary, uterus, prostate, and gastrointestinal malignancies, as well as the potential transmission of these predispositions to future generations.
What's More
The test is designed to cover not only the common hereditary cancers like breast or prostate, but also the rarer hereditary cancer types like Phaeochromocytoma and paediatric cancers such as Wilms tumor, including:
- All the clinically relevant exons
- Selected non-coding regions (BRCA1/2 5’ UTRs and the APC promoter)
- SNPs, SNVs, INDELs and CNVs
- Detection of mosaic copy number variations (such as APC and TSC2)
- Capability to accurately distinguish between PMS2 and PMS2CL pseudogene
Advantages:
- High percentage of on-target reads
- Lower duplication rates
- 99% of targets covered at 30x or more
- High precision across more variants associated with hereditary cancer
- Accurate calling of SNVs, INDELs and CNVs
- Cost-effective
- Reduced Turnaround times
- Analytical sensitivity of 100%
- Analytical specificity of 93.5%